WO2014178802A1 - Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne - Google Patents

Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne Download PDF

Info

Publication number
WO2014178802A1
WO2014178802A1 PCT/TR2013/000286 TR2013000286W WO2014178802A1 WO 2014178802 A1 WO2014178802 A1 WO 2014178802A1 TR 2013000286 W TR2013000286 W TR 2013000286W WO 2014178802 A1 WO2014178802 A1 WO 2014178802A1
Authority
WO
WIPO (PCT)
Prior art keywords
protopanaxtriol
prostatic hyperplasia
prostate cancer
composition
benign prostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2013/000286
Other languages
English (en)
Inventor
Redal Can ALKOÇLAR
Metehan YEŞIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014178802A1 publication Critical patent/WO2014178802A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a protopanaxtriol composition formed for the treatment of the prostate cancer and the benign prostatic hyperplasia.
  • the prostate cancer is a disease that occurs with the development of cancer in the prostate, which is a secretory gland associated with the male reproduction system.
  • the cancer develops when the prostate cells undergo change and begin to increase in an uncontrolled manner. These cells may in time spread from the prostate to the other regions of the body, especially the bones and the lymph (metastasis).
  • the prostate cancer may lead to such symptoms as pain, difficulty in urination and erectile dysfunction. On the other hand, these symptoms are observed only in the advancing stages of the disease.
  • testosterone and estrogen hormones underlie the cases of prostate cancer and benign prostatic hyperplasia.
  • testosterone is not converted to DHT by way of alpha reductase interaction, it interacts with aromatase to be converted to estradiol, which (the simultaneously elevated levels of testosterone and estrogen) in turn leads to the prostatic hyperplasia, and the prostate cancer in more serious conditions.
  • the invention no. US19970046236P entitled "Aryl-substituted piperazines useful in the treatment of benign prostatic hyperplasia” relates to a series of aryl-substituted piperazines of the Formula (I), the pharmaceutical compositions containing the same and the intermediates used in the manufacture of the same.
  • the compounds of the invention selectively inhibit the binding to alpha-1 a adrenergic receptor, a receptor that plays a role in the benign prostatic hyperplasia. Therefore, the compounds are potentially useful in the treatment of this disease and other diseases.
  • an object of the invention is to prevent the formation of the cancerous cells, reduce, by way of suppressing nf-kappa-b, the inflammation frequently encountered in the cases of benign prostatic hyperplasia and stimulate, owing to the antiestrogenic character, the reduction of the prostate size back to the normal.
  • Another object of the invention is to benefit from the ability of protopanaxtriol to treat the benign prostatic hyperplasia and prostate cancer, owing to the prevention of the simultaneous development of malignant cells and tissue-selective anti-estrogenic properties.
  • Another object of the invention is to enable protopanaxtriol, which reduces the level pf PSA (prostate specific antigen) effectively and within a short time, to reduce the expression of aromatase in the prostate tissues.
  • the invention is a composition for the treatment of the prostate cancer and benign prostatic hyperplasia, said composition being obtained by the components selected from the group consisting of 20-(s)- protopanaxtriol, 20-(s)-B-protopanaxtriol, 1-protopanaxtrion that are used individually or in combinations.
  • the invention is a protopanaxtriol composition formed for the treatment of the prostate cancer and the benign prostatic hyperplasia.
  • Protopanaxtriol the ingredient of the composition according to the invention, is a very active anti-mutagenic glucopyranoside derivative naturally contained by the ginseng family in trace amounts. It prevents the formation of the cancerous cells, reduces, by way of suppressing nf-kappa-b, the inflammation frequently encountered in the cases of benign prostatic hyperplasia and stimulates, owing to the anti-estrogenic character, the reduction of the prostate size back to the normal.
  • Protopanaxtriol has the ability to treat the benign prostatic hyperplasia and prostate cancer, owing to its prevention of the simultaneous development of malignant cells and its tissue-selective anti-estrogenic properties.
  • Protopanaxtriol which reduces the level of PSA (prostate specific antigen) effectively and within a short time, reduces the expression of aromatase in the prostate tissues.
  • the composition according to the invention comprises 20-(s)-protopanaxtriol, 20-(s)- B-protopanaxtriol, 1 -protopanaxtrion.
  • Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:
  • composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
  • Said invention also encompasses the use of said protopanaxtriol composition for the treatment of prostate cancer and benign prostatic hyperplasia and the manufacture thereof for this purpose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une composition destinée au traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne.
PCT/TR2013/000286 2013-04-29 2013-09-06 Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne Ceased WO2014178802A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2013/05050 2013-04-29
TR201305050 2013-04-29

Publications (1)

Publication Number Publication Date
WO2014178802A1 true WO2014178802A1 (fr) 2014-11-06

Family

ID=49515456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000286 Ceased WO2014178802A1 (fr) 2013-04-29 2013-09-06 Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne

Country Status (1)

Country Link
WO (1) WO2014178802A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103682A1 (fr) * 2002-06-11 2003-12-18 Panagin Pharmaceuticals Inc. Compositions pour le traitement du cancer comprenant des saponines ou des sapogenines
WO2004056379A1 (fr) * 2002-12-23 2004-07-08 Panagin Pharmaceuticals Inc. Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse
WO2005040189A1 (fr) * 2003-10-27 2005-05-06 Panagin Pharmaceuticals Inc. Nouvelles sapogenines dammarane, utilisation de ces dernieres en tant qu'agents anticancereux
WO2008076900A1 (fr) * 2006-12-15 2008-06-26 The Uab Research Foundation Nouveaux composés ginsénoside, compositions, et procédés d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103682A1 (fr) * 2002-06-11 2003-12-18 Panagin Pharmaceuticals Inc. Compositions pour le traitement du cancer comprenant des saponines ou des sapogenines
WO2004056379A1 (fr) * 2002-12-23 2004-07-08 Panagin Pharmaceuticals Inc. Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse
WO2005040189A1 (fr) * 2003-10-27 2005-05-06 Panagin Pharmaceuticals Inc. Nouvelles sapogenines dammarane, utilisation de ces dernieres en tant qu'agents anticancereux
WO2008076900A1 (fr) * 2006-12-15 2008-06-26 The Uab Research Foundation Nouveaux composés ginsénoside, compositions, et procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUANGTONG CHEN ET AL: "Microbial transformation of 20()-protopanaxatriol byand their cytotoxic activities against two human prostate cancer cell lines", BIOTECHNOLOGY LETTERS, SPRINGER NETHERLANDS, DORDRECHT, vol. 35, no. 1, 18 September 2012 (2012-09-18), pages 91 - 95, XP035147146, ISSN: 1573-6776, DOI: 10.1007/S10529-012-1053-X *
LI WEI ET AL: "Anti-androgen-independent prostate cancer effects of ginsenoside metabolites In Vitro: Mechanism and possible structure-activity relationship investigation", ARCHIVES OF PHARMACAL RESEARCH (SEOUL), vol. 32, no. 1, January 2009 (2009-01-01), pages 49 - 57, XP002717609, ISSN: 0253-6269 *

Similar Documents

Publication Publication Date Title
Starek-Świechowicz et al. Endogenous estrogens—breast cancer and chemoprevention
Van Duursen Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women's health
CA2503549C (fr) Compositions pharmaceutiques comprenant des derives d'estetrol a utiliser dans le traitement du cancer
Marks 5α-reductase: history and clinical importance
KR101403895B1 (ko) 유방암 및 관련 질병들에 대한 약제
Lewis et al. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal
DE69232590T2 (de) Sex steroide inhibitonen
Shang et al. Baicalein suppresses 17-β-estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway
Kang et al. Phytosterols in hull-less pumpkin seed oil, rich in∆ 7-phytosterols, ameliorate benign prostatic hyperplasia by lowing 5α-reductase and regulating balance between cell proliferation and apoptosis in rats
BRPI0516243B8 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
EP2029128B1 (fr) Procédé de traitement d'une prostatite chronique non bactérienne par des modulateurs sélectifs des récepteurs des strogènes ou par des inhibiteurs de l'aromatase
Sood et al. Relevance of aromatase inhibitors in breast cancer treatment
Xu et al. 2-Methoxy-5 ((3, 4, 5-trimethosyphenyl) seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
TW202342081A (zh) 以藥草萃取物及其組成物抑制雄性素受體
Lü et al. Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents
Wang et al. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors
Guan et al. Endocrine therapy for endometrial cancer: traditional approaches and novel targets
Shaban et al. Potential effect of Olea europea leaves, Sonchus oleraceus leaves and Mangifera indica peel extracts on aromatase activity in human placental microsomes and CYP19A1 expression in MCF-7 cell line: Comparative study
WO2014178802A1 (fr) Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne
De Santi et al. Inhibition of testosterone aromatization by the indole-3-carbinol derivative CTet in CYP19A1-overexpressing MCF-7 breast cancer cells
Yu 17β‐Estradiol epoxidation as the molecular basis for breast cancer initiation and prevention
Dhingra et al. Inhibition of aromatase and cell proliferation of breast cancer and human placenta choriocarcinoma by Prunus persica extracts
JP2022513898A (ja) エストロゲン受容体β（ＥＲβ）陽性の乳房腫瘍に対する薬物
US20080070877A1 (en) Process of epilobium species for treatment of hormone balance in warm blooded animals, and method of manufacturing
US7939517B2 (en) 1,4,6-androstatriene-3,17-dione (“ATD”) for therapeutic uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 13785676

Country of ref document: EP

Kind code of ref document: A1